118919-27-0

Upstream product

• 119777-43-4 (R)-4-Amino-4-dipentylcarbamoyl-butyric acid 
• 3024-72-4 3,4-dichlorobenzoyl chloride 
• 2050-92-2 Di-n-amylamine 
• 59486-73-6 (2R)-5-(benzyloxy)-2-{[(benzyloxy)carbonyl]amino}-5-oxopentanoic acid 
• 104252-86-0 3,4-Dichloro-N-(2,6-dioxo-tetrahydro-pyran-3-yl)-benzamide 
• 617-65-2 Glutamic acid 
• 104252-58-6 2-(3,4-Dichloro-benzoylamino)-pentanedioic acid 
• 119777-40-1 (R)-4-Benzyloxycarbonylamino-4-dipentylcarbamoyl-butyric acid benzyl ester 
• 136631-72-6 (R)-glutamic acid di-n-pentylamide γ-benzyl ester 

Relevant academic research and scientific papers

Structure-Antigastrin Activity Relationships of New (R)-4-Benzamido-5-oxopentanoic Acid Derivatives

New (R)-4-benzamido-5-oxopentanoic acid derivatives were synthesized by a stereoconservative procedure and evaluated in vitro for their capacity to inhibit the binding of (BH)-CCK-8 to either rat peripheral (CCK-A) or central (CCK-B) CCK receptors,

New glutamic and aspartic derivatives with potent CCK-antagonistic activity

New derivatives of aspartic and glutamic acid were synthesized and evaluated in vitro and in vivo for anti-CCK activity on the guinea pig gallbladder. The anti-CCK activity of some 4-benzamido-glutaramic acid derivatives was a hundred times greater than that of proglutamide, the model compound, and they have been selected for further studies.